|
|
|
 |
|
製品情報 - API Intermediates - API Intermediates
|
Avasimibe(CI-1011,PD 148515)
| カタログ : |
C13341 |
| 製品の名前: |
Avasimibe(CI-1011,PD 148515) |
| 同義語: |
CI-1011;PD 148515 |
| 化学の名前: |
N-(2,6-Dipropan-2-ylphenoxy)sulfonyl-2-(2,4,6-tripropan-2-ylphenyl)acetamide;[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester] sulfamic acid |
| CASナンバー : |
166518-60-1 |
| 構成 : |
|
| 分子式: |
C29H43NO4S |
| 分子量: |
501.72 |
| 純度: |
>99% |
| 使い方: |
Avasimibe (CI-1011) is an orally bioavailable Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) inhibitor. It was originally developed as an antilepic drug, and was shown to significantly reduce plasma total triglyceride and VLDL-cholesterol, but later clinical trials were disappointing. ACAT has also been investigated as a potential therapeutic target for Alzheimer′s disease. Recent studies have looked at the effects of avasimibe in reducing amyloid pathology by limiting generation and increasing clearance of diffusible amyloid-beta (Abeta). |
|
| 制品、有效に関する特許保護を売却せず、国家、売却こうした製品の特許侵害金人で、それは私たちの知らない特許の情况は全ての国、特許侵害責任は、十分に理解できるをバイヤーのリスクを高める. |
|
|
